Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,619.36
(
0.24%
)
Dow Jones
49,310.32
(
0.00%
)
Brent Oil
100.57
(
-0.95%
)
Bitcoin
77,811.71
(
-1.07%
)
News Focus
News Focus
Post# of 372544
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jimmybob

Send PM Follow Ignore
Followers 1877
Posts 141020
Boards Moderated 5
Alias Born 01/03/2007

jimmybob

Re: jimmybob post# 319614

Tuesday, 11/07/2017 11:43:18 AM

Tuesday, November 07, 2017 11:43:18 AM

Post# of 372544
JPMorgan still sees long road to recovery for Valeant
JPMorgan analyst Chris Schott attributes Valeant Pharmaceuticals' sales and EBITDA beat in Q3 to strong Xifaxan sales and lower than expected operating expenses. Today's results "clearly showed positive core product trends," but the company continues to have a "long road to recovery," Schott tells investors in a research note. He keeps a Neutral rating on Valeant shares. The stock in late morning trading is up 15%, or $1.80, to $13.84

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today